 |
Top 10 Gastroenterology startups in USA
Updated: May 07, 2024 |
1
Funding: $1B
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
2
Funding: $537.8M
Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
3
Funding: $441.6M
Ventyx Biosciences develops a drug for inflammatory bowel disease
Ventyx Biosciences develops a drug for inflammatory bowel disease
4
Funding: $407.2M
Synergy is a gastrointestinal-focused biopharmaceutical company committed to science-based innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.
Synergy is a gastrointestinal-focused biopharmaceutical company committed to science-based innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.
5
Funding: $173M
Metacrine is an emerging biotech company focused on developing best-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases.
Metacrine is an emerging biotech company focused on developing best-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases.
6
Funding: $150.4M
Allurion Technologies develops a medical device for weight loss that can be delivered and removed without surgery or endoscopy.
Allurion Technologies develops a medical device for weight loss that can be delivered and removed without surgery or endoscopy.
7
Funding: $95.6M
CapsoVision is a medical device company developing gastrointestinal medical devices.
CapsoVision is a medical device company developing gastrointestinal medical devices.
8
Funding: $60M
Oshi Health is a virtual-first medical practice revolutionizing the diagnosis, management and treatment of digestive health conditions.
Oshi Health is a virtual-first medical practice revolutionizing the diagnosis, management and treatment of digestive health conditions.
9
Funding: $58.8M
Vivante makes a digital program for digestive health and disease called GIThrive that includes, among other tools, a 24-7 support line to a gastrointestinal care team.
Vivante makes a digital program for digestive health and disease called GIThrive that includes, among other tools, a 24-7 support line to a gastrointestinal care team.
10
Funding: $25.7M
Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. We are discovering a new frontier in human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into safe and effective applications that can have a meaningful impact on a patient’s health.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. We are discovering a new frontier in human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into safe and effective applications that can have a meaningful impact on a patient’s health.
Ad
Advertise your startup
11
Funding: $10.5M
Salvo Health offers a virtual clinic geared toward people with chronic gut problems, including irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), dyspepsia and small intestinal bacterial overgrowth (SIBO).
Salvo Health offers a virtual clinic geared toward people with chronic gut problems, including irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), dyspepsia and small intestinal bacterial overgrowth (SIBO).
12
Funding: $8.3M
DNAlite Therapeutics committed to bringing the next-generation of drugs to organs protected by mucus barriers. Diseases such as FAP, colorectal cancer, and Crohn's disease are currently treated with complete or partial removal of the colon and/or rectum. Our aim is to prevent, rather than manage the progression of these diseases.
DNAlite Therapeutics committed to bringing the next-generation of drugs to organs protected by mucus barriers. Diseases such as FAP, colorectal cancer, and Crohn's disease are currently treated with complete or partial removal of the colon and/or rectum. Our aim is to prevent, rather than manage the progression of these diseases.
13
Funding: $6.4M
MetaMe Health is committed to developing FDA-approved prescription digital therapeutics for the treatment of gastrointestinal conditions.
MetaMe Health is committed to developing FDA-approved prescription digital therapeutics for the treatment of gastrointestinal conditions.
14
Funding: $2.2M
SmartTab is a digital medicine company which develops innovative wireless drug delivery and monitoring systems.
SmartTab is a digital medicine company which develops innovative wireless drug delivery and monitoring systems.
15
Funding: $1.5M
Kiwi Bio aims to free irritable bowel syndrome sufferers from restrictive diets. Kiwi’s product FODZYME uses patent-pending enzymes to break down common digestive triggers.
Kiwi Bio aims to free irritable bowel syndrome sufferers from restrictive diets. Kiwi’s product FODZYME uses patent-pending enzymes to break down common digestive triggers.
16
Casa de Sante is transforming gut health through convenient, personalized and virtual therapeutic care.